OncoMatch/Clinical Trials/NCT03953144

Synapse 3D With Intravascular Indocyanine Green

Is NCT03953144 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Synapse 3D Lung Modelling and IC-Green (ICG) for non-small cell lung cancer.

Treatment: Synapse 3D Lung Modelling · IC-Green (ICG) — With the advent of CT screening for lung cancer, an increasing number of NSCLCs are being detected at very early stages, and the demand for pulmonary segmentectomy is rising rapidly. As such, there is a need to develop new surgical techniques to facilitate minimally invasive pulmonary segmentectomy, as segmentectomy may provide a number of significant advantages over lobectomy for patients presenting with early-stage lung cancer, or for patients unable to undergo a full lobectomy due to existing comorbidities. This study will provide the first case series using preoperative 3D anatomical planning (Synapse 3D) added to ICG and NIF-guided robotic segmentectomy to date and will be the first reported use of Synapse 3D-guided targeted pulmonary segmental resection in Canada. As lung cancer is the most frequently fatal cancer in North America, many thousands of patients will be able to benefit from this operation every year.